Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice
Valentín García‐Gutiérrez, Alejandro Luna, Juan Manuel Alonso‐Domínguez, Natàlia Estrada, Concepción Boqué, Blanca Xicoy, Pilar Giraldo, Anna Angona, Alberto Álvarez‐Larrán, Fermín Sánchez‐Guijo, Marı́a José Ramı́rez, Elvira Mora, Patricia Vélez, Ana Rosell, Mercedes Colorado Araujo, Beatriz Cuevas, Miguel Sagüés, Montserrat Cortés, Manuel Pérez‐Encinas, Luis Felipe Casado Montero, Melania Moreno Vega, Luis Serrano, Valle Gómez, Carmen García‐Hernández, Sunil Lakhwani, Antonio Paz Coll, Raquel de Paz, Sara Suárez-Varela, A Fernandez-Ruiz, Raúl Pérez López, Almudena Ortiz-Fernández, Antonio Jiménez‐Velasco, Juan Luis Steegmann-Olmedillas, Juan Carlos Hernández‐Boluda
Abstract
Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance 1 , 2 , 3 . Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity 4 , 5 . Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses 6 , 7 , 8 .